All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.
In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen.
Company execs told ...
In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with ...
If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS by John Carroll & team — all the news at 11:30a ET
EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET